IRADIMED reports record Q2 revenue $17.9M, GAAP EPS $0.38

IRADIMED CORP

2024-Q2 EPS reported $0.71 revenue$35,526,995

Revenue of $17.9M, up 11.2% YoY; operating income $5.6M, up 13.4%.
GAAP diluted EPS $0.38; non-GAAP diluted EPS $0.42 vs $0.36 in Q2 2023.
Q3 2024 guidance: revenue $18.0-18.2M, GAAP EPS $0.34-0.37.
FY 2024 reaffirmed: revenue $72-74M, GAAP EPS $1.37-1.47.
Declares quarterly dividend $0.15/share payable Aug 30, record Aug 20.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.